Kindstar Globalgene Technology (HKG:9960) acquired a 49% equity interest in AnchorDx Inc. from AnchorDx Group HK.
The company settled the consideration for the acquisition by issuing 15,869,521 shares to WXHY Anchor Investment and 43,561,835 shares to OrbiMed Asia Partner at HK$1.42 apiece, a Friday Hong Kong bourse filing said.
Meanwhile Kindstar Global Medical Technology (Wuhan), a subsidiary of the company, also acquired 100% equity interest in Guangzhou Kangcheng Weiye Biotechnology from AnchorDx Group HK.
The group funded the acquisition consideration through internal resources and external funding.
After the completion, Guangzhou Kangcheng Weiye Biotechnology became a subsidiary of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.